Redalpine

Memo Therapeutics AG, based in Basel, Switzerland, specializes in innovative antibody discovery and immune repertoire analysis. The company utilizes its proprietary MemoMAB platform, which generates a recombinant in vitro copy of an individual's B cell or antibody repertoire, creating extensive libraries that represent unique immune responses. These libraries are expected to contain a vast array of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics applies this technology in its own antibody lead discovery programs and partners with other entities to enhance research and development in the fields of viral infections and cancer. Through its advancements, Memo Therapeutics aims to significantly improve therapeutic options for patients.

Carvolution AG is a car subscription service based in Bern, Switzerland, that provides an alternative to traditional vehicle purchasing and leasing. Founded in 2017, the company offers a fully digital platform where customers can select their desired car and pay a fixed monthly fee. This fee encompasses all essential costs such as vehicle registration, taxes, insurance, maintenance, and tires, excluding only gasoline or charging expenses. By streamlining the car ownership experience, Carvolution removes the complexities and inflexibilities associated with traditional leasing and ownership, allowing consumers to enjoy the convenience of a subscription model without long-term commitments.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.

Daedalean AG, founded in 2016 and based in Zurich, Switzerland, specializes in developing autonomous flight control systems for electric personal aircraft. The company focuses on creating machine-learning-based avionics systems for both current civil aviation and future advanced aerial mobility. With a team exceeding 150 professionals, including experts in machine learning and aviation, Daedalean is working on certification and market introduction of its AI-driven products, such as Pilot Eye™ and Ailumina Vista™, designed for visual traffic detection in fixed-wing aircraft and helicopters. Additionally, the company offers solutions for non-GNSS positioning, landing guidance, and power line detection. Daedalean has established collaborations with aviation regulators and has produced joint reports with entities like EASA and the FAA, facilitating the certification process for its innovative, safety-critical aviation applications.

Carvolution AG is a car subscription service based in Bern, Switzerland, that provides an alternative to traditional vehicle purchasing and leasing. Founded in 2017, the company offers a fully digital platform where customers can select their desired car and pay a fixed monthly fee. This fee encompasses all essential costs such as vehicle registration, taxes, insurance, maintenance, and tires, excluding only gasoline or charging expenses. By streamlining the car ownership experience, Carvolution removes the complexities and inflexibilities associated with traditional leasing and ownership, allowing consumers to enjoy the convenience of a subscription model without long-term commitments.

Memo Therapeutics AG, based in Basel, Switzerland, specializes in innovative antibody discovery and immune repertoire analysis. The company utilizes its proprietary MemoMAB platform, which generates a recombinant in vitro copy of an individual's B cell or antibody repertoire, creating extensive libraries that represent unique immune responses. These libraries are expected to contain a vast array of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics applies this technology in its own antibody lead discovery programs and partners with other entities to enhance research and development in the fields of viral infections and cancer. Through its advancements, Memo Therapeutics aims to significantly improve therapeutic options for patients.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.

Carvolution AG is a car subscription service based in Bern, Switzerland, that provides an alternative to traditional vehicle purchasing and leasing. Founded in 2017, the company offers a fully digital platform where customers can select their desired car and pay a fixed monthly fee. This fee encompasses all essential costs such as vehicle registration, taxes, insurance, maintenance, and tires, excluding only gasoline or charging expenses. By streamlining the car ownership experience, Carvolution removes the complexities and inflexibilities associated with traditional leasing and ownership, allowing consumers to enjoy the convenience of a subscription model without long-term commitments.

EraCal Therapeutics AG is a Swiss biotech company founded in 2018 and located in Schlieren, Switzerland. The company specializes in drug discovery aimed at treating various diseases, particularly focusing on obesity and its associated comorbidities. EraCal develops an innovative in-vivo screening platform that identifies appetite suppressors that selectively target food intake without causing neuronal side effects. This platform enables the creation of drugs that significantly outperform existing anti-obesity agents in both potency and selectivity, allowing patients to effectively suppress appetite and achieve weight loss.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, the company is dedicated to addressing the unmet medical needs of patients globally. Its lead candidate, VS-01, is in the preclinical stage and aims to be the first drug for acute liver disease, with the unique capability of supporting multiple organ function. VS-01 has received Orphan Drug Designation for acute liver failure, highlighting its potential in treating rare conditions. Additionally, Versantis is advancing other products in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent significant opportunities for improving patient outcomes in the field of liver health and beyond.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.

Daedalean AG, founded in 2016 and based in Zurich, Switzerland, specializes in developing autonomous flight control systems for electric personal aircraft. The company focuses on creating machine-learning-based avionics systems for both current civil aviation and future advanced aerial mobility. With a team exceeding 150 professionals, including experts in machine learning and aviation, Daedalean is working on certification and market introduction of its AI-driven products, such as Pilot Eye™ and Ailumina Vista™, designed for visual traffic detection in fixed-wing aircraft and helicopters. Additionally, the company offers solutions for non-GNSS positioning, landing guidance, and power line detection. Daedalean has established collaborations with aviation regulators and has produced joint reports with entities like EASA and the FAA, facilitating the certification process for its innovative, safety-critical aviation applications.

RosieReality, founded in 2017 and based in Zurich, Switzerland, develops an educational mobile application named Rosie, aimed at children aged 9 and up. The app utilizes augmented reality to engage kids in learning about science and basic robotics coding through interactive challenges. Users program Rosie the Robot by manipulating magical 3D shapes to solve AR puzzles, making the learning experience both fun and educational. The application is designed to foster curiosity and interest in scientific exploration, providing parents with a valuable tool for enriching their children's early education.

Carvolution AG is a car subscription service based in Bern, Switzerland, that provides an alternative to traditional vehicle purchasing and leasing. Founded in 2017, the company offers a fully digital platform where customers can select their desired car and pay a fixed monthly fee. This fee encompasses all essential costs such as vehicle registration, taxes, insurance, maintenance, and tires, excluding only gasoline or charging expenses. By streamlining the car ownership experience, Carvolution removes the complexities and inflexibilities associated with traditional leasing and ownership, allowing consumers to enjoy the convenience of a subscription model without long-term commitments.

TOLREMO therapeutics AG is a biotechnology company based in Muttenz, Switzerland, that focuses on drug discovery and the development of therapies for cancer patients. Established in 2017, the company specializes in creating small molecules aimed at targeting novel pathways associated with drug resistance in cancer treatments. TOLREMO's innovative approach includes developing add-on therapies that enhance the effectiveness of existing oncogene-targeting drugs by dismantling the mechanisms that contribute to drug resistance. By eradicating cancer cells responsible for this resistance, TOLREMO aims to provide personalized anti-drug resistance therapies, ultimately improving patient response rates and prolonging the lives of those affected by cancer.

Memo Therapeutics AG, based in Basel, Switzerland, specializes in innovative antibody discovery and immune repertoire analysis. The company utilizes its proprietary MemoMAB platform, which generates a recombinant in vitro copy of an individual's B cell or antibody repertoire, creating extensive libraries that represent unique immune responses. These libraries are expected to contain a vast array of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics applies this technology in its own antibody lead discovery programs and partners with other entities to enhance research and development in the fields of viral infections and cancer. Through its advancements, Memo Therapeutics aims to significantly improve therapeutic options for patients.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, the company is dedicated to addressing the unmet medical needs of patients globally. Its lead candidate, VS-01, is in the preclinical stage and aims to be the first drug for acute liver disease, with the unique capability of supporting multiple organ function. VS-01 has received Orphan Drug Designation for acute liver failure, highlighting its potential in treating rare conditions. Additionally, Versantis is advancing other products in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent significant opportunities for improving patient outcomes in the field of liver health and beyond.

Bexio is a Swiss-based company that helps small businesses with cloud-based business and accounting software to grow their businesses. It develops and sells accounting software for small and medium companies. Bexio was founded in 2013 and is based in Rapperswil, Zurich.

Knip AG, founded in September 2013 by Dennis Just and Christina Kehl, operates as an innovative insurance management company with offices in Zurich, Berlin, and Belgrade. The firm has grown significantly, employing over 100 staff members and receiving funding from venture capitalists across the U.S., Switzerland, Germany, and the Netherlands. Knip's primary offering is its mobile application, which allows users to manage all their insurance policies, premiums, and benefits in one place. The app facilitates tasks such as adjusting premiums, executing new policies, and canceling existing ones. Additionally, Knip provides users with biannual financial reviews to help them identify suitable tariffs and products. With a focus on transparency and unbiased advice, the company's insurance experts are available to assist users in navigating their insurance needs effectively. Knip is registered with the German Chamber of Industry & Commerce and certified by the German Technical Inspection Agency.

Memo Therapeutics AG, based in Basel, Switzerland, specializes in innovative antibody discovery and immune repertoire analysis. The company utilizes its proprietary MemoMAB platform, which generates a recombinant in vitro copy of an individual's B cell or antibody repertoire, creating extensive libraries that represent unique immune responses. These libraries are expected to contain a vast array of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics applies this technology in its own antibody lead discovery programs and partners with other entities to enhance research and development in the fields of viral infections and cancer. Through its advancements, Memo Therapeutics aims to significantly improve therapeutic options for patients.

TrekkSoft is a software solution for tour and activity providers to effectively manage and market their business. It offers a booking system, payment solution, website and mobile platform, and a channel manager. Users can sell, manage and grow their tour and activity businesses in only a few simple steps. Sell more tours by connecting your front-end and back-end sales. Manage operations by automating administration and manual tasks. Grow your business by connecting with customers around the world. TrekkSoft charges 3% or less commission rate on every activity booked online. The remaining profit gets paid out promptly to the business’ bank account with virtually no interruption to cash flow. Here are the details: Essential €50/month Online Transaction Fee 3% Offline Transaction Fee $0.60 Accelerate €100/month Online Transaction Fee 2.5% Offline Transaction Fee $0.55 Ultimate €200/month Online Transaction Fee 2% Offline Transaction Fee $0.50 Enterprise - custom pricing Custom plan available on request TrekkSoft was founded 2010 with the goal to operate a multi-client Booking engine for tour operators and activity providers. Today TrekkSoft provides online booking and reservation solutions for activity providers, tour operators, travel agents, tourist offices and event organizers. The company has offices in Interlaken, Switzerland and New York, United States. Their team consists of adventure enthusiasts, user experience specialists, marketers and expert programmers.

Bexio is a Swiss-based company that helps small businesses with cloud-based business and accounting software to grow their businesses. It develops and sells accounting software for small and medium companies. Bexio was founded in 2013 and is based in Rapperswil, Zurich.

Redbiotec is a private biotechnology company based in Zurich-Schlieren, founded in 2006 as a spin-off from ETH Zürich. The company has a history of innovation in vaccine development, having sold its cytomegalovirus (CMV) vaccine business to Pfizer in 2015 and developed an immunotherapy for herpes simplex virus type 2 (HSV-2). Currently, Redbiotec focuses on creating bacteria-based gene therapies aimed at treating cancer and genetic disorders. Utilizing a proprietary platform, the company is capable of accommodating large and diverse therapeutic cargos, effectively addressing delivery challenges that hinder other therapeutic vehicles. Redbiotec's approach includes the development of prophylactic vaccines that leverage virus-like particles targeting various viral infections, thereby contributing to unmet medical needs in the healthcare sector.

Knip AG, founded in September 2013 by Dennis Just and Christina Kehl, operates as an innovative insurance management company with offices in Zurich, Berlin, and Belgrade. The firm has grown significantly, employing over 100 staff members and receiving funding from venture capitalists across the U.S., Switzerland, Germany, and the Netherlands. Knip's primary offering is its mobile application, which allows users to manage all their insurance policies, premiums, and benefits in one place. The app facilitates tasks such as adjusting premiums, executing new policies, and canceling existing ones. Additionally, Knip provides users with biannual financial reviews to help them identify suitable tariffs and products. With a focus on transparency and unbiased advice, the company's insurance experts are available to assist users in navigating their insurance needs effectively. Knip is registered with the German Chamber of Industry & Commerce and certified by the German Technical Inspection Agency.

TrekkSoft is a software solution for tour and activity providers to effectively manage and market their business. It offers a booking system, payment solution, website and mobile platform, and a channel manager. Users can sell, manage and grow their tour and activity businesses in only a few simple steps. Sell more tours by connecting your front-end and back-end sales. Manage operations by automating administration and manual tasks. Grow your business by connecting with customers around the world. TrekkSoft charges 3% or less commission rate on every activity booked online. The remaining profit gets paid out promptly to the business’ bank account with virtually no interruption to cash flow. Here are the details: Essential €50/month Online Transaction Fee 3% Offline Transaction Fee $0.60 Accelerate €100/month Online Transaction Fee 2.5% Offline Transaction Fee $0.55 Ultimate €200/month Online Transaction Fee 2% Offline Transaction Fee $0.50 Enterprise - custom pricing Custom plan available on request TrekkSoft was founded 2010 with the goal to operate a multi-client Booking engine for tour operators and activity providers. Today TrekkSoft provides online booking and reservation solutions for activity providers, tour operators, travel agents, tourist offices and event organizers. The company has offices in Interlaken, Switzerland and New York, United States. Their team consists of adventure enthusiasts, user experience specialists, marketers and expert programmers.

Onsite Lab Holding AG, based in Zug, Switzerland, focuses on the development and manufacture of rapid flow-through diagnostics and technologies primarily for HIV and hepatitis viruses. Through its subsidiary MedMira, the company offers advanced rapid tests that deliver results within three minutes, facilitating quick and efficient diagnosis. These products are designed for use in point-of-care settings, laboratories, and hospitals, both in the United States and internationally. MedMira's patented technology allows for multiple results in a single test, enhancing its utility in mass testing scenarios. The company emphasizes high-quality standards while ensuring economical sustainability, with its facilities holding various certifications, including ISO and approvals from FDA and CE.

TrekkSoft is a software solution for tour and activity providers to effectively manage and market their business. It offers a booking system, payment solution, website and mobile platform, and a channel manager. Users can sell, manage and grow their tour and activity businesses in only a few simple steps. Sell more tours by connecting your front-end and back-end sales. Manage operations by automating administration and manual tasks. Grow your business by connecting with customers around the world. TrekkSoft charges 3% or less commission rate on every activity booked online. The remaining profit gets paid out promptly to the business’ bank account with virtually no interruption to cash flow. Here are the details: Essential €50/month Online Transaction Fee 3% Offline Transaction Fee $0.60 Accelerate €100/month Online Transaction Fee 2.5% Offline Transaction Fee $0.55 Ultimate €200/month Online Transaction Fee 2% Offline Transaction Fee $0.50 Enterprise - custom pricing Custom plan available on request TrekkSoft was founded 2010 with the goal to operate a multi-client Booking engine for tour operators and activity providers. Today TrekkSoft provides online booking and reservation solutions for activity providers, tour operators, travel agents, tourist offices and event organizers. The company has offices in Interlaken, Switzerland and New York, United States. Their team consists of adventure enthusiasts, user experience specialists, marketers and expert programmers.

InSphero AG specializes in the development of organotypic biological 3D microtissues and microtissue-based assays, aimed at enhancing in vitro testing for drug discovery and toxicity assessment. Founded in 2009 and headquartered in Schlieren, Switzerland, the company provides a variety of products including liver, pancreas, and tumor microtissues, as well as custom-made microtissues and specialized kits. InSphero's 3D cell culture platforms, such as the GravityTRAP ultra-low attachment plate, facilitate the generation and analysis of scaffold-free 3D microtissue spheroids. Their offerings also extend to cytotoxicity assay kits and services for hepatotoxicity testing, cancer research, and stem cell applications. The technology developed by InSphero enables researchers to obtain biologically relevant insights, improving the predictive power of drug testing and reducing reliance on animal testing.

Redvax is a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. Redvax is a preclinical stage company. The company develops multi-component virus-like particles (VLPs) and other protein assemblies for vaccine development in the field of CMV and a further undisclosed field.